Drugs / Calcium alpha-ketoglutarate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07269704 | Aug 2023 → Jun 2025 | eye disorder | Stanford University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Calcium alpha-ketoglutarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07269704 ↗ |
| Route | Oral | “Participants took 2 g/day of calcium alpha-ketoglutarate orally, twice daily, for 7 days.” NCT07269704 ↗ |